PR88780

MADRID, March 31, 2021 /PRNewswire=KYODO JBN/ --

- mAbxience, a global fully-fledged biotech company, with over a decade of

experience in the development, manufacture and commercialization of

biopharmaceuticals, is expanding patient access to biological treatments

throughout Europe.

The European Commission (EC) has approved mAbxience's MB02 biosimilar to

Avastin(R) (Bevacizumab), in Europe.

MB02, to be commercialized as Alymsys(R) and Oyavas(R), is highly similar to

the reference medicinal product and data has shown a comparable quality, safety

and efficacy to Avastin(R). MB02 is intended for the treatment of carcinoma of

the colon or rectum, breast cancer, non-small cell lung cancer, renal cell

cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and

carcinoma of the cervix.

"We are currently witnessing a period of vital importance globally, with a key

focus on the healthcare system and its sustainability," said Emmanuelle Lepine,

General Manager at mAbxience.

"The launch of our Bevacizumab under the trademarks Alymsys(R) and Oyavas(R) in

the European market will be a perfect example of how innovation and

cutting-edge R&D technology can be applied to obtain a high quality, affordable

medicine which, as well as providing alternatives for the healthcare system,

will also improve patient access to costly treatments."

About mAbxience

mAbxience is a fully integrated global biopharmaceutical company specialising

in the development, manufacture and commercialization of monoclonal antibodies,

and forms part of the pharmaceutical group Insud Pharma. Founded in 2010,

mAbxience operates three state of the art facilities, located in Spain and

Argentina. mAbxience is working on several biopharmaceutical products spanning

to different therapeutic areas. In 2014 mAbxience launched its first

biosimilar, Rituximab (Product Code: RTXM83-MB01), which is now approved and

marketed in a range of markets worldwide. Its second product, Bevacizumab

(Product Code: BEVZ92-MB02), was first developed and launched in Latin America

in 2016.

mAbxience is committed to the quality, safety and efficacy of its medicines.

The mAbxience team is passionate about patient care and expanding access to its

biopharmaceutical medicines all over the world. The Company's mission is to

improve patient access to quality treatments for conditions that require costly

medications and positively contributing to the sustainability of healthcare

systems.

The Insud Pharma Group was founded by Dr. Hugo Sigman and Dr. Silvia Gold and

has over 40 years' experience in the pharmaceutical sector and employs over

6,000 professionals worldwide.

Disclaimer

Some of the statements in this press release other than statements of

historical fact, may be forward-looking statements or statements of future

expectations based on currently available information. Such statements are

naturally subject to risks and uncertainties, same as our business, as well as

each product we develop and market, is subject to various risks and

uncertainties beyond our control. Forward-looking statements represent the

judgment of mAbxience's management as of the date of this release, and

mAbxience disclaims any intent or obligation to update any forward-looking

statements contained herein, which speak as of the date hereof.

Source: mAbxience